PO.PR01.03 · 预防研究
利用整合蛋白质组学与多变量模式分析识别初治非裔美国女性乳腺癌特异性血清蛋白质特征
Serum protein signatures specific to breast cancer in treatment-naive African American women identified using integrated proteomics and multivariate pattern analysis
该海报暂无可下载的资料
AACR 官方页面
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景:乳腺癌是非裔美国女性发病和死亡的首要原因。识别人群特异性血清生物标志物对于早期检测和风险分层至关重要。为克服传统单变量分析的局限性,我们开发了一个整合平台,将经典蛋白质组学(2D-DIGE、MALDI-TOF/TOF、LC-MS/MS)与随机森林(RF)和基于累积分布函数(CDF)的分析相结合,以稳健地发现并验证血清生物标志物。
人群:在去除高丰度蛋白质后,对两个初治非裔美国女性队列进行了检查。主队列包括11例乳腺癌患者(中位年龄50岁,范围29-74岁)以及11例年龄匹配的健康对照,通过2D-DIGE和MALDI-TOF/TOF进行分析。另一个独立队列包括6例患者和6例对照,通过LC-MS/MS(MudPIT)进行评估。患者涵盖绝经前和绝经后状态以及多样的肿瘤亚型和受体谱。对照为无癌症病史的健康女性。
方法:采用2D-DIGE凝胶结合MALDI-TOF/TOF的蛋白质组学分析可检测和识别差异表达的血清蛋白质。LC-MS/MS数据采用RF(1,000次自举迭代)进行分析,使用Gini重要性对肽段相关性进行排序,CDF则使用源自1,000次置换的S统计量评估分布差异(S阈值大于或等于3)。RF与CDF的结合能够在高维度、共线性以及可能的非高斯分布条件下检测出相关信号。
结果:该整合方法揭示了乳腺癌中多种差异表达的血清蛋白质。代表性生物标志物包括铜蓝蛋白(Ceruloplasmin)、补体C3、Alpha-1B-糖蛋白、血管紧张素原前体、胰岛素样生长因子结合蛋白复合物酸不稳定亚基、血红素结合蛋白前体(Hemopexin precursor)以及维生素D结合蛋白。互补的2D-DIGE和MALDI-TOF/TOF分析可直接确定这些差异蛋白质模式,而LC-MS/MS结合RF和CDF则优先筛选出具有高判别力的肽段,并独立确认了它们的统计学显著性。
结论:将经典蛋白质组学技术(2D-DIGE和MALDI-TOF/TOF)与LC-MS/MS结合RF和CDF分析相整合,能够可靠地检测和优先筛选血清生物标志物。该方法将多变量蛋白质组学的敏感性与非参数统计的严谨性相结合,适用于小规模、高维度的队列,并展现出识别代表性不足人群特异性生物标志物的潜力,从而支持乳腺癌精准肿瘤学的应用。
查看英文原文 English abstract
Background: Breast cancer is the leading cause of morbidity and mortality among African American women. Identifying population-specific serum biomarkers is essential for early detection and risk stratification. To address limitations of traditional univariate analyses, we developed an integrated platform combining classical proteomics (2D-DIGE, MALDI-TOF/TOF, LC-MS/MS) with Random Forest (RF) and cumulative distribution function (CDF)-based analyses to robustly discover and validate serum biomarkers.
Population: Two cohorts of treatment-naïve African American women were examined following depletion of high-abundance proteins. The primary cohort included eleven breast cancer patients median age 50 years, range 29-74, and 11 age-matched healthy controls analyzed by 2D-DIGE and MALDI-TOF/TOF. An independent cohort of 6 patients and 6 controls was assessed by LC-MS/MS (MudPIT). Patients represented both pre- and postmenopausal status and diverse tumor subtypes and receptor profiles. Controls were healthy women without a cancer history.
Methods: Proteomic analysis using 2D-DIGE gels combined with MALDI-TOF/TOF allowed the detection and identification of differentially expressed serum proteins. LC-MS/MS data were analyzed with RF (1,000 bootstrap iterations) using Gini importance to rank peptide relevance, and the CDF evaluated distribution differences using an S statistic derived from 1,000 permutations (S threshold greater than or equal to 3). The combination of RF and CDF enabled the detection of relevant signals under conditions of high dimensionality, collinearity, and potentially non-Gaussian distributions.
Results: The integrated approach revealed multiple differentially expressed serum proteins in breast cancer. Representative biomarkers included Ceruloplasmin, Complement C3; Alpha-1B-glycoprotein, angiotensinogen precursor, Insulin-like growth factor-binding protein complex acid labile subunit, Hemopexin precursor, and vitamin D binding protein. Complementary 2D-DIGE and MALDI-TOF/TOF analyses allowed direct determination of these differential protein patterns, while LC-MS/MS combined with RF and CDF prioritized peptides with high discriminatory power and independently confirmed their statistical significance.
Conclusion: The integration of classical proteomics techniques (2D-DIGE and MALDI-TOF/TOF) with LC-MS/MS combined with RF and CDF analysis enables reliable detection and prioritization of serum biomarkers. This approach combines the sensitivity of multivariate proteomics with non-parametric statistical rigor, making it suitable for small, high-dimensional cohorts, and demonstrates potential for identifying biomarkers specific to underrepresented populations, supporting precision oncology applications in breast cancer.
利益披露 Disclosure
P. P. Tadi Uppala, None..
H. J. Kwon, None..
E. C. Rivera, None..
S. S. Lum, None.